And since you mentioned chatgpt here is the response to are iPSC's safe. I didn't bring chatgpt up by the way, so now I guess you will say they are out of date?ChatGPT said:are ipsc's safeGreat question — let’s unpack that carefully.
Induced pluripotent stem cells (iPSCs) are a type of stem cell created by reprogramming adult somatic cells (like skin or blood cells) to revert them into a pluripotent state, meaning they can differentiate into almost any cell type in the body. They’re hugely valuable for research, drug testing, disease modeling, and regenerative medicine.
As for safety — it depends on the context of their use.
Here’s a breakdown:✅ iPSC Safety Positives:
Ethically preferable: No embryos are destroyed to create them.
Patient-specific potential: You can generate iPSCs from a patient’s own cells, minimizing the risk of immune rejection.
Lab research & disease modeling: In vitro uses are considered safe.
⚠️ iPSC Safety Concerns:
Genetic instability: The reprogramming process can introduce genetic mutations or epigenetic abnormalities.
Tumorigenicity: Like embryonic stem cells, iPSCs can form teratomas (benign tumors of mixed tissue) if undifferentiated cells are transplanted.
Reprogramming factors: Traditional methods used viral vectors to introduce genes like c-Myc, which is oncogenic (cancer-promoting). Newer, safer techniques (non-integrating methods like episomal vectors, mRNA, or CRISPR-based systems) reduce this risk but aren’t entirely risk-free.
Incomplete differentiation: If cells aren’t fully or correctly differentiated before transplantation, unintended effects can occur.
Current Status:
In lab and preclinical contexts, they’re widely used and relatively safe.
In clinical trials (there are a handful ongoing globally — e.g., for macular degeneration, Parkinson’s), safety is still being rigorously tested.
Regulatory authorities like the FDA or EMA closely oversee any therapeutic use.
In summary:
✅ Safe in lab research.
⚠️ Potential risks for clinical applications — being actively addressed through better reprogramming, differentiation, and screening techniques.
- Forums
- ASX - By Stock
- CYP
- Ann: CYP-001s FDA Approval Pathway Not Impeded
CYP
cynata therapeutics limited
Add to My Watchlist
2.94%
!
16.5¢

Ann: CYP-001s FDA Approval Pathway Not Impeded, page-12
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
16.5¢ |
Change
-0.005(2.94%) |
Mkt cap ! $37.28M |
Open | High | Low | Value | Volume |
16.5¢ | 17.0¢ | 16.5¢ | $38.44K | 230.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 277685 | 16.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
17.0¢ | 8128 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 277685 | 0.165 |
7 | 1307381 | 0.160 |
3 | 26451 | 0.155 |
3 | 115000 | 0.150 |
3 | 48937 | 0.140 |
Price($) | Vol. | No. |
---|---|---|
0.170 | 8128 | 2 |
0.175 | 21397 | 2 |
0.180 | 113494 | 5 |
0.185 | 94565 | 3 |
0.190 | 143868 | 3 |
Last trade - 14.35pm 16/06/2025 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |